Find a Researcher
Artak Tovmasyan, PharmD, PhD, is an assistant professor in the Department of Translational Neuroscience at Barrow Neurological Institute. He directs the pharmacokinetics core laboratory at the Ivy Brain Tumor Center.
Dr. Tovmasyan’s expertise includes pharmaceutical sciences and drug development, particularly in the field of neuro-oncology. He is a member of the American Association for Cancer Research, the Society for Neuro-Oncology, the Society for Redox Biology and Medicine, and the Society for Porphyrins and Phthalocyanines.
Dr. Tovmasyan earned his PharmD and PhD degrees from the Yerevan State Medical University School of Pharmacy in Armenia, where he also completed a residency in drug development. He completed a postdoctoral fellowship in the Department of Radiation Oncology, Division of Cancer Biology at Duke University Medical Center.
Dr. Tovmasyan’s work in the pharmacokinetics core laboratory involves evaluating drugs used in Phase 0 clinical trials for brain tumor patients. The results obtained in this state-of-the-art laboratory enable doctors to implement the most efficient brain tumor treatment regimens. The lab also provides services in the assessment and design of preclinical pharmacokinetics studies for experimental drugs, collection and processing of specimens, publishing guidance, and assistance with grant applications. Dr. Tovmasyan’s research interests also include medicinal chemistry in the design and development of agents that target the brain, particularly novel radio-modulators for brain tumor therapy.
- Postdoctoral Fellowship, Duke University Medical Center, Department of Radiation Oncology-Cancer Biology, 2009-2014
- PhD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Pharmaceutical Sciences, 2008
- Residency, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2004-2005
- Internship, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2003-2004
- PharmD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, 2003
- American Association of Cancer Research
- Society for Neuro-Oncology
- Society for Redox Biology and Medicine
- Society of Porphyrins and Phthalocyanines
- Young Investigator Award, 23rd Annual Meeting of Society for Redox Biology and Medicine, 2016
- Young Investigator Award, Duke Cancer Institute, National Cancer Institute Radiation Oncology and Imaging Program Annual Retreat, 2016
- Fellowship Award at Emory University School of Medicine, Society for Redox Biology and Medicine, 2014
- Nominee, National Comprehensive Cancer Network Young Investigator Award, Duke University, 2014
- Fellowship, Friedrich-Alexander University Erlangen-Nürnberg, Department of Bioinorganic Chemistry, 2013
- Fellowship, University of Bourgogne, Institute of Molecular Chemistry, 2008
- Best Oral Presentation, 4th Young Medics’ International Conference, Armenian Medical Association, 2007
- Graduate Research Support Program Award, National Foundation of Science and Advanced Technologies, US Civilian Research and Development Foundation, 2006
- Travel Grant, Yerevan State Medical University, 2006
- Best Oral Presentation, 3rd Young Medics’ International Conference, National Academy of Sciences, 2005
- Travel Grant, 3rd Young Medics’ International Conference, Young Medics’ Association, 2005
Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
Date: 11/2025
Authors: Kevin C. Johnson, An-Chi Tien, Jun Jiang, James McNamara, Yu-Wei Chang, Chelsea Montgomery, Anita DeSantis, Leonel Elena-Sanchez, Yoko Fujita, Seongho Kim, Avishay Spitzer, Paul Gabriel, William F. Flynn, Elise T. Courtois, Amy Hong, Jocelyn Harmon, Yoshie Umemura, Artak Tovmasyan, Jing Li, Shwetal Mehta, Roel G. Verhaak, Nader Sanai
Manganese Porphyrin Reduces Oxidative Stress in Vulnerable Parkin-Null Drosophila Dopaminergic Neurons
Date: 08/2025
Authors: Amber N. Juba, Petros P. Keoseyan, Riley P. Hamel, Tigran Margaryan, Michaela L. Barber, Amanda N. Foley, T Bucky Jones, Ines Batinic-Haberle, Artak Tovmasyan, Lori M. Buhlman
park+/+ and park-/- Drosophila have sexually dimorphic brain redox chemistry
Date: 08/2025
Authors: Amber N. Juba, Bobbi Stwalley, Tigran Margaryan, Riley Hamel, Amanda N. Foley, T Bucky Jones, Artak Tovmasyan, Lori M. Buhlman
Protoporphyrin IX plasma and blood pharmacokinetics and brain tumor distribution determined by a validated LC-MS/MS method
Date: 07/2025
Authors: William Knight, Tigran Margaryan, Kamal Shaik, Nader Sanai, Artak Tovmasyan
Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors
Date: 03/2025
Authors: Jing Li, Charuka Wickramasinghe, Jun Jiang, Andrew Wu, Yuanyuan Jiang, Artak Tovmasyan, Seongho Kim, Nader Sanai
Artak Tovmasyan, PharmD, PhD, is an assistant professor in the Department of Translational Neuroscience at Barrow Neurological Institute. He directs the pharmacokinetics core laboratory at the Ivy Brain Tumor Center.
Dr. Tovmasyan’s expertise includes pharmaceutical sciences and drug development, particularly in the field of neuro-oncology. He is a member of the American Association for Cancer Research, the Society for Neuro-Oncology, the Society for Redox Biology and Medicine, and the Society for Porphyrins and Phthalocyanines.
Dr. Tovmasyan earned his PharmD and PhD degrees from the Yerevan State Medical University School of Pharmacy in Armenia, where he also completed a residency in drug development. He completed a postdoctoral fellowship in the Department of Radiation Oncology, Division of Cancer Biology at Duke University Medical Center.
Dr. Tovmasyan’s work in the pharmacokinetics core laboratory involves evaluating drugs used in Phase 0 clinical trials for brain tumor patients. The results obtained in this state-of-the-art laboratory enable doctors to implement the most efficient brain tumor treatment regimens. The lab also provides services in the assessment and design of preclinical pharmacokinetics studies for experimental drugs, collection and processing of specimens, publishing guidance, and assistance with grant applications. Dr. Tovmasyan’s research interests also include medicinal chemistry in the design and development of agents that target the brain, particularly novel radio-modulators for brain tumor therapy.
- Postdoctoral Fellowship, Duke University Medical Center, Department of Radiation Oncology-Cancer Biology, 2009-2014
- PhD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Pharmaceutical Sciences, 2008
- Residency, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2004-2005
- Internship, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2003-2004
- PharmD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, 2003
- American Association of Cancer Research
- Society for Neuro-Oncology
- Society for Redox Biology and Medicine
- Society of Porphyrins and Phthalocyanines
- Young Investigator Award, 23rd Annual Meeting of Society for Redox Biology and Medicine, 2016
- Young Investigator Award, Duke Cancer Institute, National Cancer Institute Radiation Oncology and Imaging Program Annual Retreat, 2016
- Fellowship Award at Emory University School of Medicine, Society for Redox Biology and Medicine, 2014
- Nominee, National Comprehensive Cancer Network Young Investigator Award, Duke University, 2014
- Fellowship, Friedrich-Alexander University Erlangen-Nürnberg, Department of Bioinorganic Chemistry, 2013
- Fellowship, University of Bourgogne, Institute of Molecular Chemistry, 2008
- Best Oral Presentation, 4th Young Medics’ International Conference, Armenian Medical Association, 2007
- Graduate Research Support Program Award, National Foundation of Science and Advanced Technologies, US Civilian Research and Development Foundation, 2006
- Travel Grant, Yerevan State Medical University, 2006
- Best Oral Presentation, 3rd Young Medics’ International Conference, National Academy of Sciences, 2005
- Travel Grant, 3rd Young Medics’ International Conference, Young Medics’ Association, 2005
Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
Date: 11/2025
Authors: Kevin C. Johnson, An-Chi Tien, Jun Jiang, James McNamara, Yu-Wei Chang, Chelsea Montgomery, Anita DeSantis, Leonel Elena-Sanchez, Yoko Fujita, Seongho Kim, Avishay Spitzer, Paul Gabriel, William F. Flynn, Elise T. Courtois, Amy Hong, Jocelyn Harmon, Yoshie Umemura, Artak Tovmasyan, Jing Li, Shwetal Mehta, Roel G. Verhaak, Nader Sanai
Manganese Porphyrin Reduces Oxidative Stress in Vulnerable Parkin-Null Drosophila Dopaminergic Neurons
Date: 08/2025
Authors: Amber N. Juba, Petros P. Keoseyan, Riley P. Hamel, Tigran Margaryan, Michaela L. Barber, Amanda N. Foley, T Bucky Jones, Ines Batinic-Haberle, Artak Tovmasyan, Lori M. Buhlman
park+/+ and park-/- Drosophila have sexually dimorphic brain redox chemistry
Date: 08/2025
Authors: Amber N. Juba, Bobbi Stwalley, Tigran Margaryan, Riley Hamel, Amanda N. Foley, T Bucky Jones, Artak Tovmasyan, Lori M. Buhlman
Protoporphyrin IX plasma and blood pharmacokinetics and brain tumor distribution determined by a validated LC-MS/MS method
Date: 07/2025
Authors: William Knight, Tigran Margaryan, Kamal Shaik, Nader Sanai, Artak Tovmasyan
Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors
Date: 03/2025
Authors: Jing Li, Charuka Wickramasinghe, Jun Jiang, Andrew Wu, Yuanyuan Jiang, Artak Tovmasyan, Seongho Kim, Nader Sanai